Summary
Cystic fibrosis (CF) a monogenic lethal disease and, therefore, ideally suited for the development of gene therapy. The first clinical trials were carried out shortly after cloning the CF gene in 1989. Since then, 25 trials have been carried out. Proof of principle for low-level airway gene transfer was established in most, but not all, trials. It is currently unclear whether current gene transfer efficiency will lead to improvements in clinically relevant endpoints such as inflammation or infection. In addition to addressing this important question, we and others are further improving airway gene transfer, by modifying existing and developing new gene transfer agents. Here, we describe pre-clinical methods related to assessing correction of the CF chloride transport defect.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., and Chou, J. L. (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245, 1066–1073.
Alton, E. W., Middleton, P. G., Caplen, N. J., Smith, S. N., Steel, D. M., Munkonge, F. M., Jeffery, P. K., Geddes, D. M., Hart, S. L., and Williamson, R. (1993) Non-invasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice. Nat. Genet. 5, 135–142.
Drumm, M. L., Pope, h. A., Cliff, W. h., Rommens, J. M., Marvin, S. A., Tsui, L. C., Collins, F. S., Frizzell, R. A., and Wilson, J. M. 1990) Correction of the cystic fibrosis defect in vitro by etrovirus-mediated gene transfer. Cell 62, 1227–1233.
Hyde, S. C., Gill, D. R., Higgins, C. F., Trezise, A. E., MacVinish, L. J., Cuthbert, A. W., Ratcliff, R., Evans, M. J., and Colledge, W. h. 1993) Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy. Nature 362, 250–255.
Konstan, M. W., Davis, P. B., Wagener, J. S., Hilliard, K. A., Stern, R. C., Milgram, L. J., Kowalczyk, T. h., Hyatt, S. L., Fink, T. L., Gedeon, C. R., Oette, S. M., Payne, J. M., Muhammad, O., Ziady, A. G., Moen, R. C., and Cooper, M. J. 2004) Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum. Gene Ther. 15, 1255–1269.
Moss, R. B., Rodman, D., Spencer, L. T., Aitken, M. L., Zeitlin, P. L., Waltz, D., Milla, C., Brody, A. S., Clancy, J. P., Ramsey, B., Hamblett, N., and Heald, A. E. 2004) Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 125, 509–521.
Engelhardt, J. F., Yankaskas, J. R., Ernst, S. A., Yang, Y., Marino, C. R., Boucher, R. C., Cohn, J. A., and Wilson, J. M. 1992) Submucosal glands are the predominant site of CFTR expression in the human bronchus. Nat. Genet. 2, 240–248.
Ferrari, S., Griesenbach, U., Geddes, D. M., and Alton, E. 2003) Immunological hurdles to lung gene therapy. Clin. Exp. Immunol. 132, 1–8.
Venglarik, C. J., Bridges, R. J., and Frizzell, R. A. 1990) A simple assay for agonist-regulated Cl and K conductances in salt-secreting epithelial cells. Am. J. Physiol. 259, C358–C364.
Wright, E. M. and Diamond, J. M. 1977) Anion selectivity in biological systems. Physiol. Rev. 57, 109–156.
Derand, R., Bulteau-Pignoux, L., and Becq, F. 2003) Comparative pharmacology of the activity of wild-type and G551D mutated CFTR chloride channel: effect of the benzimidazolone derivative NS004. J. Membr. Biol. 194, 109–117.
Baggot, D. 1978) Pharmacokinetics of kanamycin in the dog. J. Vet. Pharmacol. Ther. 1, 163–170s.
Dorin, J. R. 2006) Animal Models in Progress in Respiratory Research: Cystic Fibrosis in the 21st Century (eds: A. Bush, E. Alton, J Davies, U Griesenbach, A Jaffe), Karger, London, 84–92.
Zhou, L., Dey, C. R., Wert, S. E., DuVall, M. D., Frizzell, R. A., and Whitsett, J. A. 1994) Correction of lethal intestinal defect in a mouse model of cystic fibrosis by human CFTR. Science 266, 1705–1708.
Jiang, C., O’Connor, S. P., Fang, S. L., Wang, K. X., Marshall, J., Williams, J. L., Wilburn, B., Echelard, Y., and Cheng, S. h. 1998) Efficiency of cationic lipid-mediated transfection of polarized and differentiated airway epithelial cells in vitro and in vivo. Hum. Gene Ther. 9, 1531–1542.
Smith, S. N., Middleton, P. G., Chadwick, S., Jaffe, A., Bush, K. A., Rolleston, S., Farley, R., Delaney, S. J., Wainwright, B., Geddes, D. M., and Alton, E. W. 1999) The in vivo effects of milrinone on the airways of cystic fibrosis mice and human subjects. Am. J. Respir. Cell Mol. Biol. 20, 129–134.
Acknowledgments
The work was funded by the CF Trust and a Senior CF Trust Fellowship (U.G.). We thank Lucinda Somerton for help with preparing the manuscript.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Griesenbach, U. et al. (2008). Assessment of CFTR Function after Gene Transfer In Vitro and In Vivo. In: Gene Therapy Protocols. Methods in Molecular Biology™, vol 433. Humana Press. https://doi.org/10.1007/978-1-59745-237-3_14
Download citation
DOI: https://doi.org/10.1007/978-1-59745-237-3_14
Publisher Name: Humana Press
Print ISBN: 978-1-58829-903-1
Online ISBN: 978-1-59745-237-3
eBook Packages: Springer Protocols